Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Wu, Yi-Long"" wg kryterium: Autor


Tytuł:
Emerging evidence and treatment paradigm of non-small cell lung cancer.
Autorzy:
Liu SM; Department of Hematology, The First Affiliated Hospital, Jinan University, Guangzhou, 510632, China.
Zheng MM; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 106 Zhongshan Er Road, Guangzhou, 510080, China.
Pan Y; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 106 Zhongshan Er Road, Guangzhou, 510080, China.
Liu SY; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 106 Zhongshan Er Road, Guangzhou, 510080, China.
Li Y; Department of Hematology, The First Affiliated Hospital, Jinan University, Guangzhou, 510632, China. .; Institute of Hematology, School of Medicine, Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University, Guangzhou, 510632, China. .
Wu YL; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 106 Zhongshan Er Road, Guangzhou, 510080, China. .; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, China. .
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2023 Apr 17; Vol. 16 (1), pp. 40. Date of Electronic Publication: 2023 Apr 17.
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/drug therapy
Humans ; Immunotherapy/methods ; Programmed Cell Death 1 Receptor ; B7-H1 Antigen
Czasopismo naukowe
Tytuł:
Sublobectomy for stage IA1-2 invasive lung adenocarcinoma with consolidation tumor ratio ≤ 0.25.
Autorzy:
Qi YF; School of Medicine, South China University of Technology, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.; Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Qiu ZB; School of Medicine, South China University of Technology, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.; Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Zhang C; School of Medicine, South China University of Technology, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.; Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Fu R; School of Medicine, South China University of Technology, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.; Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Yang XW; School of Medicine, South China University of Technology, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.; Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Chu XP; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.; Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Chen ZH; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.; Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.; The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.
Yang XN; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.; Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Wu YL; School of Medicine, South China University of Technology, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.; Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Zhong WZ; School of Medicine, South China University of Technology, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.; Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2022 Nov; Vol. 13 (22), pp. 3174-3182. Date of Electronic Publication: 2022 Oct 08.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/surgery
Lung Neoplasms*/pathology
Adenocarcinoma of Lung*/surgery
Adenocarcinoma of Lung*/pathology
Adenocarcinoma*/surgery
Adenocarcinoma*/pathology
Humans ; Pneumonectomy ; Neoplasm Staging ; Neoplasm Recurrence, Local/pathology
Czasopismo naukowe
Tytuł:
Dynamic F-FDG PET/CT can predict the major pathological response to neoadjuvant immunotherapy in non-small cell lung cancer.
Autorzy:
Chen ZY; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Fu R; School of Medicine, South China University of Technology, Guangzhou, China.; Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Tan XY; Department of Nuclear Medicine, WeiLun PET/CT Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Yan LX; Department of Pathology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Tang WF; Department of Cardiothoracic Surgery, Zhongshan City People's Hospital, Zhongshan, Guangdong, China.
Qiu ZB; Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Qi YF; School of Medicine, South China University of Technology, Guangzhou, China.; Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Li YF; Department of Pathology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Hou QY; Department of Nuclear Medicine, WeiLun PET/CT Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Wu YL; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.; School of Medicine, South China University of Technology, Guangzhou, China.; Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Zhong WZ; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.; School of Medicine, South China University of Technology, Guangzhou, China.; Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Jiang BY; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2022 Sep; Vol. 13 (17), pp. 2524-2531. Date of Electronic Publication: 2022 Jul 12.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/diagnostic imaging
Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/diagnostic imaging
Lung Neoplasms*/drug therapy
Fluorodeoxyglucose F18 ; Humans ; Immunotherapy ; Neoadjuvant Therapy ; Positron Emission Tomography Computed Tomography/methods ; Positron-Emission Tomography ; Reproducibility of Results ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Clinical outcomes of EGFR+/METamp+ vs. EGFR+/METamp- untreated patients with advanced non-small cell lung cancer.
Autorzy:
Peng KC; School of Medicine, South China University of Technology, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Su JW; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Xie Z; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Wang HM; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Fang MM; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Li WF; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Chen YQ; School of Medicine, South China University of Technology, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Guan XH; School of Medicine, South China University of Technology, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Su J; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Yan HH; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Zhang XC; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Tu HY; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Zhou Q; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Chen HJ; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Wu YL; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Yang JJ; School of Medicine, South China University of Technology, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2022 Jun; Vol. 13 (11), pp. 1619-1630. Date of Electronic Publication: 2022 Apr 18.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
Pleural Effusion, Malignant*/drug therapy
ErbB Receptors/genetics ; ErbB Receptors/therapeutic use ; Humans ; Mutation ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use
Czasopismo naukowe
Tytuł:
Intratumoral genetic and immune microenvironmental heterogeneity in T4N0M0 (diameter ≥ 7 cm) non-small cell lung cancers.
Autorzy:
Zhang JT; The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.
Dong S; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Ji LY; Geneplus-Beijing Institute, Beijing, China.
Zhou JY; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Chen ZH; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Su J; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Zhu QG; Geneplus-Beijing Institute, Beijing, China.
Wang MM; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Ke EE; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Sun H; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Li XT; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Yang JJ; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Zhou Q; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Zhang XC; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Gao X; Geneplus-Beijing Institute, Beijing, China.
Yang XN; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Xia X; Geneplus-Beijing Institute, Beijing, China.
Yi X; Geneplus-Beijing Institute, Beijing, China.
Zhong WZ; The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Wu YL; The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2022 May; Vol. 13 (9), pp. 1333-1341. Date of Electronic Publication: 2022 Apr 08.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/genetics
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
DNA Copy Number Variations ; Genetic Heterogeneity ; Humans ; Mutation ; Tumor Microenvironment/genetics ; Exome Sequencing
Czasopismo naukowe
Tytuł:
Poor prognosis of intra-tumoural TRBV6-6 variants in EGFR-mutant NSCLC: Results from the ADJUVANT-CTONG1104 trial.
Autorzy:
Chen C; Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou, China.
Liu SM; Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou, China.; Department of Hematology, First Affiliated Hospital, The Clinical Medicine Postdoctoral Research Station, Jinan University, Guangzhou, China.; Chinese Thoracic Oncology Group (CTONG), Guangzhou, China.
Chen Y; Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China.
Han M; Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China.
Ou Q; Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China.
Bao H; Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China.
Xu L; Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou, China.
Zhang Y; Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou, China.
Zhang JT; Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangdong Lung Cancer Institute, Guangzhou, China.
Zhong W; Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangdong Lung Cancer Institute, Guangzhou, China.
Zhou Q; Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangdong Lung Cancer Institute, Guangzhou, China.
Yang XN; Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangdong Lung Cancer Institute, Guangzhou, China.
Shao Y; Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China.; School of Public Health, Nanjing Medical University, Nanjing, China.
Wu YL; Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangdong Lung Cancer Institute, Guangzhou, China.
Liu SY; Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangdong Lung Cancer Institute, Guangzhou, China.
Li Y; Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou, China.
Pokaż więcej
Źródło:
Clinical and translational medicine [Clin Transl Med] 2022 Apr; Vol. 12 (4), pp. e775.
Typ publikacji:
Letter; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
ErbB Receptors/genetics ; Humans ; Prognosis
Raport
Tytuł:
High SHP2 expression determines the efficacy of PD-1/PD-L1 inhibitors in advanced KRAS mutant non-small cell lung cancer.
Autorzy:
Feng HB; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Medical Research Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China.
Chen Y; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Medical Research Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China.
Xie Z; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Medical Research Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China.
Jiang J; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Medical Research Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China.
Zhong YM; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Medical Research Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China.
Guo WB; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Medical Research Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China.
Yan WQ; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Medical Research Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China.
Lv ZY; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Medical Research Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China.
Lu DX; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Medical Research Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China.
Liang HL; Department of Surgical Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.
Xu FP; Department of Pathology and Laboratory Medicine, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.
Yang JJ; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Medical Research Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China.; The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.
Yang XN; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Medical Research Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China.
Zhou Q; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Medical Research Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China.; The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.
Zhang DK; Department of Thoracic Surgery, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.
Zhang Z; Burning Rock Biotech, Shanghai, China.
Chuai SK; Burning Rock Biotech, Shanghai, China.
Zhang HH; Genecast Biotechnology, Wuxi, China.
Wu YL; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Medical Research Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China.; The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.
Zhang XC; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Medical Research Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2021 Oct; Vol. 12 (19), pp. 2564-2573. Date of Electronic Publication: 2021 Sep 06.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Non-Small-Cell Lung/*drug therapy
Carcinoma, Non-Small-Cell Lung/*genetics
Immune Checkpoint Inhibitors/*pharmacology
Immunotherapy/*methods
Lung Neoplasms/*drug therapy
Lung Neoplasms/*genetics
Protein Tyrosine Phosphatase, Non-Receptor Type 11/*genetics
Aged ; Female ; Humans ; Male ; Middle Aged ; Mutation ; Proto-Oncogene Proteins p21(ras)/genetics ; Retrospective Studies ; Tumor Microenvironment/drug effects ; Tumor Microenvironment/genetics
Czasopismo naukowe
Tytuł:
Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer.
Autorzy:
Ni J; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
Huang M; Peking University Cancer Hospital, Beijing, China.
Zhang L; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
Wu N; Peking University Cancer Hospital, Beijing, China.
Bai CX; Zhongshan Hospital, Fudan University, Shanghai, China.
Chen LA; The First Medical Center of Chinese PLA General Hospital, Beijing, China.
Liang J; Peking University International Hospital, Beijing, China.
Liu Q; Chinese Journal of Lung Cancer, Beijing, China.
Wang J; National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Wu YL; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Zhang FC; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
Zhang SY; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
Chen C; Fujian Medical University Union Hospital, Fuzhou, China.
Chen J; Tianjin Medical University General Hospital, Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin, China.
Fang WT; Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Gao SG; National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Hu J; The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, China.
Jiang T; Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Li SQ; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
Li HC; Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Liao YD; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Liu Y; The First Medical Center of Chinese PLA General Hospital, Beijing, China.
Liu DR; China-Japan Friendship Hospital, Beijing, China.
Liu HX; Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China.
Liu JY; Jilin Cancer Hospital, Changchun, China.
Liu LX; West China Hospital, Sichuan University, Chengdu, China.
Wang MZ; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
Wang CL; National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Yang F; Peking University People's Hospital, Beijing, China.
Yang Y; Peking University Cancer Hospital, Beijing, China.
Zhang LJ; Sun Yat-sen University Cancer Center, Guangzhou, China.
Zhi XY; Xuanwu Hospital, Capital Medical University, Beijing, China.
Zhong WZ; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Guan YZ; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
Guo XX; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
He CX; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
Li SL; Peking University Cancer Hospital, Beijing, China.
Li Y; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
Liang NX; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
Lu FL; Peking University Cancer Hospital, Beijing, China.
Lv C; Peking University Cancer Hospital, Beijing, China.
Lv W; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
Si XY; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
Tan FW; National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Wang HP; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
Wang JS; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
Yan S; Peking University Cancer Hospital, Beijing, China.
Yang HX; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
Zhu HJ; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
Zhuang JL; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
Zhuo ML; Peking University Cancer Hospital, Beijing, China.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2021 May; Vol. 12 (9), pp. 1469-1488. Date of Electronic Publication: 2021 Mar 30.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung/*complications
Immunotherapy/*adverse effects
Lung Neoplasms/*complications
Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/pathology ; Female ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/pathology ; Male ; Perioperative Period
Czasopismo naukowe
Tytuł:
Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patients.
Autorzy:
Chen JH; The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Key Laboratory of Lung Cancer Translational Medicine, South China University of Technology & Guangdong Academy of Medical Sciences, Guangzhou, China.; Guangzhou Twelfth People's Hospital, Guangzhou, China.
Chu XP; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Key Laboratory of Lung Cancer Translational Medicine, South China University of Technology & Guangdong Academy of Medical Sciences, Guangzhou, China.
Zhang JT; The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Key Laboratory of Lung Cancer Translational Medicine, South China University of Technology & Guangdong Academy of Medical Sciences, Guangzhou, China.
Nie Q; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Key Laboratory of Lung Cancer Translational Medicine, South China University of Technology & Guangdong Academy of Medical Sciences, Guangzhou, China.
Tang WF; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Key Laboratory of Lung Cancer Translational Medicine, South China University of Technology & Guangdong Academy of Medical Sciences, Guangzhou, China.; Shantou University Medical College, Shantou, China.
Su J; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Key Laboratory of Lung Cancer Translational Medicine, South China University of Technology & Guangdong Academy of Medical Sciences, Guangzhou, China.
Yan HH; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Key Laboratory of Lung Cancer Translational Medicine, South China University of Technology & Guangdong Academy of Medical Sciences, Guangzhou, China.
Zheng HP; Accurate International Biotechnology Co., Guangzhou, China.
Chen ZX; Accurate International Biotechnology Co., Guangzhou, China.
Chen X; Accurate International Biotechnology Co., Guangzhou, China.
Song MM; Geneplus-Beijing Institute, Beijing, China.
Yi X; Geneplus-Beijing Institute, Beijing, China.
Li PS; Geneplus-Beijing Institute, Beijing, China.
Guan YF; Geneplus-Beijing Institute, Beijing, China.
Li G; The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.
Deng CX; University of Macau. Cancer Centre, Faculty of Health Sciences, University of Macau, Macau, China.
Rosell R; Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Campus Can Ruti (Edifici Muntanya), Ctra. de Can Ruti, Barcelona, Spain.
Wu YL; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Key Laboratory of Lung Cancer Translational Medicine, South China University of Technology & Guangdong Academy of Medical Sciences, Guangzhou, China.
Zhong WZ; The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Key Laboratory of Lung Cancer Translational Medicine, South China University of Technology & Guangdong Academy of Medical Sciences, Guangzhou, China.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2020 Aug; Vol. 11 (8), pp. 2279-2290. Date of Electronic Publication: 2020 Jul 07.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Non-Small-Cell Lung/*genetics
Drug Evaluation, Preclinical/*methods
Genomics/*methods
Lung Neoplasms/*genetics
Organoids/*pathology
Aged ; Carcinoma, Non-Small-Cell Lung/pathology ; Female ; Humans ; Lung Neoplasms/pathology ; Male ; Middle Aged
Czasopismo naukowe
Tytuł:
Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer.
Autorzy:
Wei XW; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China.
Gao X; The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.
Zhang XC; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China.
Yang JJ; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China.
Chen ZH; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China.
Wu YL; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China.
Zhou Q; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China.; The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2020 Jun; Vol. 11 (6), pp. 1512-1521. Date of Electronic Publication: 2020 Apr 14.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Mutation*
Adenocarcinoma of Lung/*pathology
Biomarkers, Tumor/*genetics
Carcinoma, Non-Small-Cell Lung/*pathology
Carcinoma, Squamous Cell/*pathology
Lung Neoplasms/*pathology
Receptor, ErbB-2/*genetics
Adenocarcinoma of Lung/genetics ; Aged ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Squamous Cell/genetics ; Female ; Follow-Up Studies ; High-Throughput Nucleotide Sequencing ; Humans ; Lung Neoplasms/genetics ; Male ; Prognosis ; Survival Rate
Czasopismo naukowe
Tytuł:
Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study.
Autorzy:
Lu C; The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Dong XR; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zhao J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department I of Thoracic Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
Zhang XC; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Chen HJ; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Zhou Q; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Tu HY; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Ai XH; Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Chen XF; Oncology Department, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
An GL; Department of Clinical Oncology, Shaanxi Provincial People's Hospital, Xi'an, China.
Bai J; Department of Clinical Oncology, Shaanxi Provincial People's Hospital, Xi'an, China.
Shan JL; Daping Hospital, Army medical center of PLA, Chongqing, China.
Wang YN; Department of Oncology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China.
Yang SY; The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Liu X; Department of Cardiothoracic Surgery, The Second Affiliated Hospital, University of South China, Hengyang, China.
Zhuang W; Fujian Provincial Cancer Hospital, Fuzhou, China.
Wu HT; Department of Oncology, Zhongshan Hospital, Xiamen University, Xiamen, China.
Zhu B; Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, China.
Xia XF; Geneplus-Beijing Institute, Beijing, China.
Chen RR; Geneplus-Beijing Institute, Beijing, China.
Gu DJ; Geneplus-Beijing Institute, Beijing, China.
Xu HM; Geneplus-Beijing Institute, Beijing, China.
Wu YL; The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China. .; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. .
Yang JJ; The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China. .; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. .
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2020 Apr 15; Vol. 13 (1), pp. 37. Date of Electronic Publication: 2020 Apr 15.
Typ publikacji:
Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Non-Small-Cell Lung/*genetics
Lung Neoplasms/*genetics
Proto-Oncogene Proteins c-ret/*genetics
Adult ; Aged ; Aged, 80 and over ; B7-H1 Antigen/genetics ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/epidemiology ; Female ; Gene Rearrangement ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Lung Neoplasms/drug therapy ; Lung Neoplasms/epidemiology ; Male ; Middle Aged ; Mutation ; Retrospective Studies ; Survival Analysis ; Tumor Suppressor Protein p53/genetics ; Young Adult
Czasopismo naukowe
Tytuł:
Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma-like carcinoma.
Autorzy:
Yin K; The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Medical Research Center, Cancer Center, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China.
Feng HB; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Medical Research Center, Cancer Center, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China.
Li LL; The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Medical Research Center, Cancer Center, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China.
Chen Y; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Medical Research Center, Cancer Center, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China.
Xie Z; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Medical Research Center, Cancer Center, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China.
Lv ZY; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Medical Research Center, Cancer Center, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China.
Guo WB; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Medical Research Center, Cancer Center, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China.
Lu DX; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Medical Research Center, Cancer Center, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China.
Yang XN; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Medical Research Center, Cancer Center, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China.
Yan WQ; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Medical Research Center, Cancer Center, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China.
Wu YL; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Medical Research Center, Cancer Center, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China.
Zhang XC; The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Medical Research Center, Cancer Center, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2020 Feb; Vol. 11 (2), pp. 346-352. Date of Electronic Publication: 2019 Dec 03.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Gene Rearrangement*
Mutation*
Anaplastic Lymphoma Kinase/*genetics
Biomarkers, Tumor/*genetics
Carcinoma, Non-Small-Cell Lung/*pathology
Lung Neoplasms/*pathology
Adolescent ; Adult ; Aged ; Carcinoma, Non-Small-Cell Lung/genetics ; ErbB Receptors/genetics ; Female ; Follow-Up Studies ; Humans ; Lung Neoplasms/genetics ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Survival Rate ; Young Adult
Czasopismo naukowe
Tytuł:
Recursive partitioning analysis of patients with oligometastatic non-small cell lung cancer: a retrospective study.
Autorzy:
Zhang JT; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Key Laboratory of Lung Cancer Translational Medicine, South China University of Technology & Guangdong Academy of Medical Sciences, Guangzhou, 510080, China.
Liu SY; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Key Laboratory of Lung Cancer Translational Medicine, South China University of Technology & Guangdong Academy of Medical Sciences, Guangzhou, 510080, China.
Yan HH; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Key Laboratory of Lung Cancer Translational Medicine, South China University of Technology & Guangdong Academy of Medical Sciences, Guangzhou, 510080, China.
Wu YL; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Key Laboratory of Lung Cancer Translational Medicine, South China University of Technology & Guangdong Academy of Medical Sciences, Guangzhou, 510080, China.
Nie Q; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Key Laboratory of Lung Cancer Translational Medicine, South China University of Technology & Guangdong Academy of Medical Sciences, Guangzhou, 510080, China. .
Zhong WZ; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Key Laboratory of Lung Cancer Translational Medicine, South China University of Technology & Guangdong Academy of Medical Sciences, Guangzhou, 510080, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2019 Nov 06; Vol. 19 (1), pp. 1051. Date of Electronic Publication: 2019 Nov 06.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung/*radiotherapy
Carcinoma, Non-Small-Cell Lung/*surgery
Lung Neoplasms/*radiotherapy
Lung Neoplasms/*surgery
Adult ; Aged ; Aged, 80 and over ; Carcinoma, Non-Small-Cell Lung/pathology ; Combined Modality Therapy ; Female ; Humans ; Kaplan-Meier Estimate ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Staging ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Emerging therapies for non-small cell lung cancer.
Autorzy:
Zhang C; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, People's Republic of China.; School of Medicine, South China University of Technology, Guangzhou, People's Republic of China.
Leighl NB; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Wu YL; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, People's Republic of China.
Zhong WZ; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, People's Republic of China. .
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2019 Apr 25; Vol. 12 (1), pp. 45. Date of Electronic Publication: 2019 Apr 25.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms:
Carcinoma, Non-Small-Cell Lung/*drug therapy
Immunotherapy/*methods
Lung Neoplasms/*drug therapy
Carcinoma, Non-Small-Cell Lung/pathology ; Humans ; Lung Neoplasms/pathology
Czasopismo naukowe
Tytuł:
Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.
Autorzy:
Chen RL; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital and Guangdong Academy of Medical Sciences, 106 Zhongshan 2nd Road, Guangzhou, 510080, China.
Zhao J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Medical Oncology, Peking University Cancer Hospital and Institute, Beijing, China.
Zhang XC; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital and Guangdong Academy of Medical Sciences, 106 Zhongshan 2nd Road, Guangzhou, 510080, China.
Lou NN; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital and Guangdong Academy of Medical Sciences, 106 Zhongshan 2nd Road, Guangzhou, 510080, China.; Department of Radiation Oncology, Xiaolan People's Hospital Affiliated to Southern Medical University, Zhongshan, Guangdong, China.
Chen HJ; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital and Guangdong Academy of Medical Sciences, 106 Zhongshan 2nd Road, Guangzhou, 510080, China.
Yang X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Medical Oncology, Peking University Cancer Hospital and Institute, Beijing, China.
Su J; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital and Guangdong Academy of Medical Sciences, 106 Zhongshan 2nd Road, Guangzhou, 510080, China.
Xie Z; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital and Guangdong Academy of Medical Sciences, 106 Zhongshan 2nd Road, Guangzhou, 510080, China.
Zhou Q; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital and Guangdong Academy of Medical Sciences, 106 Zhongshan 2nd Road, Guangzhou, 510080, China.
Tu HY; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital and Guangdong Academy of Medical Sciences, 106 Zhongshan 2nd Road, Guangzhou, 510080, China.
Zhong WZ; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital and Guangdong Academy of Medical Sciences, 106 Zhongshan 2nd Road, Guangzhou, 510080, China.
Yan HH; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital and Guangdong Academy of Medical Sciences, 106 Zhongshan 2nd Road, Guangzhou, 510080, China.
Guo WB; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital and Guangdong Academy of Medical Sciences, 106 Zhongshan 2nd Road, Guangzhou, 510080, China.
Wu YL; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital and Guangdong Academy of Medical Sciences, 106 Zhongshan 2nd Road, Guangzhou, 510080, China. .
Yang JJ; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital and Guangdong Academy of Medical Sciences, 106 Zhongshan 2nd Road, Guangzhou, 510080, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2018 Nov 26; Vol. 18 (1), pp. 1171. Date of Electronic Publication: 2018 Nov 26.
Typ publikacji:
Journal Article
MeSH Terms:
Gene Expression*
Gene Rearrangement*
Antineoplastic Agents/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Carcinoma, Non-Small-Cell Lung/*genetics
Crizotinib/*therapeutic use
Lung Neoplasms/*drug therapy
Lung Neoplasms/*genetics
Protein Kinase Inhibitors/*therapeutic use
Adult ; Aged ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/pathology ; Female ; Gene Amplification ; Genes, erbB-1 ; Humans ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Mutation ; Neoplasm Staging ; Proto-Oncogene Proteins p21(ras)/genetics ; Retrospective Studies ; Survival Analysis
Czasopismo naukowe
Tytuł:
Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.
Autorzy:
Kang J; Guangdong Cardiovascular Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.; Division of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.
Chen HJ; Division of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.
Zhang XC; Division of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.
Su J; Division of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.
Zhou Q; Division of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.
Tu HY; Division of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.
Wang Z; Division of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.
Wang BC; Division of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.
Zhong WZ; Division of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.
Yang XN; Division of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.
Chen ZH; Division of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.
Ding Y; Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, Ontario, Canada.
Wu X; Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, Ontario, Canada.
Wang M; BioScience Department, Dizal (Jiangsu) Pharmaceutical Co. Ltd, Shanghai, China.
Fu JG; BioScience Department, Dizal (Jiangsu) Pharmaceutical Co. Ltd, Shanghai, China.
Yang Z; BioScience Department, Dizal (Jiangsu) Pharmaceutical Co. Ltd, Shanghai, China.
Zhang X; Medical Department, Nanjing Geneseeq Technology Inc., Nanjing, China.
Shao YW; Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, Ontario, Canada.; School of Public Health, Nanjing Medical University, Nanjing, China.
Wu YL; Division of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.; Medical Research Center, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.
Yang JJ; Guangdong Cardiovascular Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.; Division of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2018 Sep; Vol. 9 (9), pp. 1093-1103. Date of Electronic Publication: 2018 Jul 06.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Anaplastic Lymphoma Kinase/*genetics
Carcinoma, Non-Small-Cell Lung/*genetics
Carcinoma, Non-Small-Cell Lung/*pathology
Crizotinib/*pharmacology
Drug Resistance, Bacterial/*genetics
Lung Neoplasms/*genetics
Lung Neoplasms/*pathology
Protein Kinase Inhibitors/*pharmacology
Anaplastic Lymphoma Kinase/antagonists & inhibitors ; Biomarkers, Tumor ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/mortality ; Crizotinib/therapeutic use ; DNA Mutational Analysis ; Gene Expression Profiling ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/mortality ; Mutation ; Neoplasm Metastasis ; Neoplasm Staging ; Prognosis ; Protein Kinase Inhibitors/therapeutic use
Czasopismo naukowe
Tytuł:
Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer.
Autorzy:
Nishio M; Thoracic Oncology Center, The Cancer Institute Hospital of JFCR, Tokyo, Japan.
Kim DW; Seoul National University Hospital, Seoul, Korea.
Wu YL; Guangdong Lung Cancer Institute, Guangdong, China.
Nakagawa K; Kindai University, Osaka, Japan.
Solomon BJ; Peter MacCallum Cancer Centre, Melbourne, Australia.
Shaw AT; Massachusetts General Hospital, Boston, MA, USA.
Hashigaki S; Pfizer Oncology, Tokyo, Japan.
Ohki E; Pfizer Oncology, Tokyo, Japan.
Usari T; Pfizer Oncology, Milan, Italy.
Paolini J; Pfizer Oncology, Milan, Italy.
Polli A; Pfizer Oncology, Milan, Italy.
Wilner KD; Pfizer Oncology, La Jolla, CA, USA.
Mok T; State Key Laboratory of South China, Hong Kong Cancer Institute and The Chinese University of Hong Kong, Shatin, China.
Pokaż więcej
Źródło:
Cancer research and treatment [Cancer Res Treat] 2018 Jul; Vol. 50 (3), pp. 691-700. Date of Electronic Publication: 2017 Jul 06.
Typ publikacji:
Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial
MeSH Terms:
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lung Neoplasms/*drug therapy
Pemetrexed/*administration & dosage
Pyrazoles/*administration & dosage
Pyridines/*administration & dosage
Receptor Protein-Tyrosine Kinases/*genetics
Taxoids/*administration & dosage
Anaplastic Lymphoma Kinase ; Carcinoma, Non-Small-Cell Lung/genetics ; Crizotinib ; Docetaxel ; Drug Administration Schedule ; Female ; Humans ; Intention to Treat Analysis ; Kaplan-Meier Estimate ; Lung Neoplasms/genetics ; Male ; Pemetrexed/adverse effects ; Pyrazoles/adverse effects ; Pyridines/adverse effects ; Survival Analysis ; Taxoids/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł:
The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer.
Autorzy:
Zhang YC; Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan 2nd Road, Guangzhou, Guangdong, 510080, People's Republic of China.
Zhou Q; Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan 2nd Road, Guangzhou, Guangdong, 510080, People's Republic of China.
Wu YL; Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan 2nd Road, Guangzhou, Guangdong, 510080, People's Republic of China. .
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2017 Oct 23; Vol. 10 (1), pp. 167. Date of Electronic Publication: 2017 Oct 23.
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Non-Small-Cell Lung/*genetics
Liquid Biopsy/*methods
Lung Neoplasms/*genetics
Carcinoma, Non-Small-Cell Lung/pathology ; Humans ; Lung Neoplasms/pathology
Czasopismo naukowe
Tytuł:
A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).
Autorzy:
Zhou Q; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, 106 Zhongshan 2nd Road, Guangzhou, 510080, Guangdong, China.
Song Y; Nanjing General Hospital of Nanjing Military Command, Nanjing, Jiangsu, China.
Zhang X; Zhongshan Hospital, Shanghai, China.
Chen GY; The Tumor Hospital affiliated to Harbin Medical University, Harbin, Heilongjiang, China.
Zhong DS; General Hospital of Tianjin Medical University, Heping, Tianjin, China.
Yu Z; The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Yu P; Sichuan Cancer Hospital, Chengdu, Sichuan, China.
Zhang YP; Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
Chen JH; Hunan Cancer Hospital, Changsha, Hunan, China.
Hu Y; Chinese PLA General Hospital, Beijing, China.
Feng GS; The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China.
Song X; Shanxi Cancer Hospital, Taiyuan, Shanxi, China.
Shi Q; Lilly Suzhou Pharmaceutical Co., Ltd, Shanghai, China.
Yang LL; Lilly Suzhou Pharmaceutical Co., Ltd, Shanghai, China.
Zhang PH; Lilly Suzhou Pharmaceutical Co., Ltd, Shanghai, China.
Wu YL; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, 106 Zhongshan 2nd Road, Guangzhou, 510080, Guangdong, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2017 Jul 03; Vol. 17 (1), pp. 462. Date of Electronic Publication: 2017 Jul 03.
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Health Care Surveys*
Practice Patterns, Physicians'*
Carcinoma, Non-Small-Cell Lung/*epidemiology
Lung Neoplasms/*epidemiology
Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Carcinoma, Non-Small-Cell Lung/diagnosis ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/therapy ; China/epidemiology ; Female ; Genetic Testing ; Genetic Variation ; Humans ; Lung Neoplasms/diagnosis ; Lung Neoplasms/genetics ; Lung Neoplasms/therapy ; Male ; Middle Aged ; Molecular Targeted Therapy ; Neoplasm Metastasis ; Neoplasm Staging
Czasopismo naukowe
Tytuł:
Supraclavicular lymph node incisional biopsies have no influence on the prognosis of advanced non-small cell lung cancer patients: a retrospective study.
Autorzy:
Dong S; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Science, 106 Zhongshan 2nd Road, Guangzhou, 510080, People's Republic of China.
Zhao N; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Science, 106 Zhongshan 2nd Road, Guangzhou, 510080, People's Republic of China.; Department of Thoracic Surgery, The First People's Hospital of Foshan, Foshan, People's Republic of China.
Deng W; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Science, 106 Zhongshan 2nd Road, Guangzhou, 510080, People's Republic of China.; Southern Medical University, Guangzhou, People's Republic of China.
Sun HW; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Science, 106 Zhongshan 2nd Road, Guangzhou, 510080, People's Republic of China.; Southern Medical University, Guangzhou, People's Republic of China.
Niu FY; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Science, 106 Zhongshan 2nd Road, Guangzhou, 510080, People's Republic of China.; Southern Medical University, Guangzhou, People's Republic of China.
Yang JJ; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Science, 106 Zhongshan 2nd Road, Guangzhou, 510080, People's Republic of China.
Zhong WZ; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Science, 106 Zhongshan 2nd Road, Guangzhou, 510080, People's Republic of China.
Li F; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Science, 106 Zhongshan 2nd Road, Guangzhou, 510080, People's Republic of China.; Southern Medical University, Guangzhou, People's Republic of China.
Yan HH; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Science, 106 Zhongshan 2nd Road, Guangzhou, 510080, People's Republic of China.
Xu CR; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Science, 106 Zhongshan 2nd Road, Guangzhou, 510080, People's Republic of China.
Zhang QY; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Science, 106 Zhongshan 2nd Road, Guangzhou, 510080, People's Republic of China.; Southern Medical University, Guangzhou, People's Republic of China.
Yang XN; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Science, 106 Zhongshan 2nd Road, Guangzhou, 510080, People's Republic of China.
Liao RQ; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Science, 106 Zhongshan 2nd Road, Guangzhou, 510080, People's Republic of China.
Nie Q; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Science, 106 Zhongshan 2nd Road, Guangzhou, 510080, People's Republic of China.
Wu YL; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Science, 106 Zhongshan 2nd Road, Guangzhou, 510080, People's Republic of China. .
Pokaż więcej
Źródło:
World journal of surgical oncology [World J Surg Oncol] 2017 Jan 09; Vol. 15 (1), pp. 12. Date of Electronic Publication: 2017 Jan 09.
Typ publikacji:
Journal Article
MeSH Terms:
Adenocarcinoma/*secondary
Carcinoma, Large Cell/*secondary
Carcinoma, Non-Small-Cell Lung/*secondary
Carcinoma, Squamous Cell/*secondary
Lung Neoplasms/*pathology
Lymph Nodes/*surgery
Neoplasm Recurrence, Local/*pathology
Adenocarcinoma/surgery ; Adult ; Aged ; Aged, 80 and over ; Carcinoma, Large Cell/surgery ; Carcinoma, Non-Small-Cell Lung/surgery ; Carcinoma, Squamous Cell/surgery ; Female ; Follow-Up Studies ; Humans ; Lung Neoplasms/surgery ; Lymph Node Excision ; Lymph Nodes/pathology ; Lymphatic Metastasis ; Male ; Middle Aged ; Neoplasm Recurrence, Local/surgery ; Neoplasm Staging ; Prognosis ; Retrospective Studies ; Survival Rate
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies